Accelerating Access Initiative

Widening access to care and support for people living with HIV/AIDS. Widening access to care and support for people living with HIV/AIDS. Copyright World Health Organization

Description of partnership activities and how they address needs and challenges

The Accelerating Access Initiative (AAI), begun in 2000, was a partnership between UNAIDS, the World Health Organization (WHO), the UN Children's Fund (UNICEF), the UN Population Fund (UNFPA), the World Bank and research-based pharmaceutical companies. Participants in AAI are committed to working with governments, international organizations and other stakeholders to find ways to broaden access, whilst ensuring rational, safe and effective use of medicines for HIV/AIDS.

The strong commitment of the AAI companies to improving access to treatment manifested itself in many innovative ways. All AAI companies had individual programs through which they provided their own antiretroviral medicines at more affordable prices in developing countries. Some AAI companies expanded manufacturing capacity to meet product demand in the developing world. Individual AAI companies also took other actions to increase the overall availability of ARVs, including the granting of voluntary licenses or non-assert declarations, contract manufacturing with generic manufacturers and technology transfer agreements. These efforts are delivered results:in September 2008, 773,803 patients in developing countries were estimated to be taking one or more medicines supplied at preferential prices by an AAI company. In addition, the number of patients in developing countries treated with generic ARVs - including those through cooperative efforts with AAI companies - increased significantly.

AAI partners recognize that expanded access to medications requires a collaborative approach with governments, NGOs, multilateral organizations, and other public and private bodies. Many AAI companies involved in initiatives to strengthen healthcare systems streamline product registrations and conduct clinical studies in developing countries. AAI companies also invested significantly in research and development of new medications - including pediatric formulations - and diagnostics, to help combat the global HIV/AIDS pandemic.

Partnership information

Company(ies) Boehringer Ingelheim , Bristol-Myers Squibb , GlaxoSmithKline , MSD , Pfizer , Roche

Partner(s) UNAIDS, UNFPA, UNICEF, ViiV Healthcare, World Bank, World Health Organization (WHO)

Type of Partner(s) IGOs, Other Business

Therapeutic Focus Infectious Diseases

Disease(s) HIV/AIDS

Program Type(s) Availability of Treatment - Product Donations, Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How

Targeted Population(s) Children, Elderly, Men, Mothers, People with low income, Women, Youth

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, Middle East & North Africa, South Asia, Sub-Saharan Africa

Number of Countries 147

Country(ies) Afghanistan, Albania, Algeria, Angola, Antigua and Barbuda, Argentina, Armenia, Azerbaijan, Bangladesh, Belarus, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Costa Rica, Côte d'Ivoire, Cuba, Czech Republic, Democratic Republic of the Congo, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Eritrea, Ethiopia, Fiji, Gabon, Georgia, Ghana, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, India, Indonesia, Iran, Iraq, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kosovo, Kyrgyzstan, Lao PDR, Lebanon, Lesotho, Liberia, Libya, Lithuania, Macedonia, Madagascar, Malawi, Malaysia, Maldives, Mali, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Moldova, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nepal, Nicaragua, Niger, Nigeria, Niue, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Romania, Russia, Rwanda, Samoa, Sao Tome and Principe, Senegal, Serbia, Seychelles, Sierra Leone, Slovakia, Solomon Islands, Somalia, South Africa, South Korea, Sri Lanka, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, Sudan, Suriname, Swaziland, Syria, Tajikistan, Tanzania, Thailand, The Gambia, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Tuvalu, Uganda, Ukraine, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, West Bank and Gaza, Yemen, Zambia, Zimbabwe

Start Date 2002

More information AAI Progress Report

Completed date 2012